BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics’ Advanced Platform
CAMBRIDGE, Mass. and SHENZHEN, China, July 22, 2014 /PRNewswire/ — BGI Tech Solutions Co., LTD, (BGI Tech), a subsidiary of BGI, the world’s largest genomics organization, announced the global launch of a new human whole exome sequencing service based on Complete Genomics’ industry-leading platform.
Complete Genomics, highly regarded in the industry for providing proprietary sequencing technologies with 99.999% accuracy and highly sensitive detection of all types of variants, was acquired by BGI in 2013. More than 15,000 human genomes have been sequenced and analyzed on the Complete Genomics platform to date. BGI, applying its deep genome and exome sequencing expertise, has enriched Complete Genomics’ platform further to now enable robust and rapid human whole exome sequencing services that leverage the inherent strengths of that platform.
Whole exome sequencing on Complete Genomics’ platform, available beginning today at introductory pricing of only $599 per sample through year-end 2014, guarantees 100X average sequencing depth for target regions and includes analysis for SNP/InDel calling and annotation as well as SNP validation. In addition, BGI Tech provides a dedicated workflow and pipeline addressing cancer study design and challenges, enabling sensitive detection of somatic variants in the presence of tumor heterogeneity.
Yingrui Li, CEO of BGI Tech, stated, "We are pleased to make this extremely accurate platform available to our more than 30,000 customers worldwide and to the global research community. We currently are developing additional applications of this platform, such as transcriptome analysis and genotyping by sequencing, and look forward to announcing their availability soon."
For more information, visit bgitechsolutions.com/complete-genomics-offers.